Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2012/174199 International Application No.: PCT/US2012/042387
Publication Date: 20.12.2012 International Filing Date: 14.06.2012
C07D 471/04 (2006.01)
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
in which the condensed system contains two hetero rings
Ortho-condensed systems
MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, NJ 07065-0907, US (AllExceptUS)
FIJI, Hannah, D. [US/US]; US (NZ, US)
KELLY, Michael, J., III [US/US]; US (NZ, US)
KERN, Jeffrey, C. [US/US]; US (NZ, US)
LAYTON, Mark, E. [US/US]; US (NZ, US)
PERO, Joseph, E. [US/US]; US (NZ, US)
REIF, Alexander, J. [US/US]; US (NZ, US)
ROSSI, Michael, A. [US/US]; US (NZ, US)
FIJI, Hannah, D.; US
KELLY, Michael, J., III; US
KERN, Jeffrey, C.; US
LAYTON, Mark, E.; US
PERO, Joseph, E.; US
REIF, Alexander, J.; US
ROSSI, Michael, A.; US
MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue Rahway, NJ 07065-0907, US
Priority Data:
(EN) The present invention is directed to imidazopyridin-2-one derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
(FR) La présente invention concerne des dérivés d'imidazopyridin-2-one qui sont des potentialisateurs des récepteurs métabotropes du glutamate, notamment le récepteur mGluR2, et qui sont utiles dans le traitement ou la prévention de troubles neurologiques et psychiatriques associés à un dysfonctionnement du glutamate et de maladies dans lesquelles les récepteurs métabotropes du glutamate sont impliqués. L'invention concerne également des compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés et compositions dans la prévention ou le traitement de ces maladies dans lesquelles les récepteurs métabotropes du glutamate sont impliqués.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as: